Abstract:Background: Almost a decade after its approval, sorafenib remains the only approved therapy for advanced hepatocellular carcinoma (HCC). Novel treatment is warranted for advanced HCC. Previous preclinical studies reported that inhibition of various cyclin dependent kinases (CDKs), whether cell cycle dependent or independent, showed activity against HCC. Dinaciclib is a potent inhibitor of CDK1, 2, 5, and 9 and has an acceptable safety profile in humans. We thus examined the efficacy of dinaciclib in HCC using preclinical models. Methods: In a panel of HCC cell lines with high Rb expression (HuH7, PLC5, HepG2, SK-Hep1, SNU387, SNU449, SNU426 and SNU475) and low Rb expression (Hep3B and HLE), dinaciclib was examined for its effect on cell viability. The impacts of dinaciclib on cell cycle distribution, apoptosis induction, and the expressions of phospho- (p-) Rb (the target of CDK1 and 2), p-ATM (the target of CDK5), c-myc, and p-RNA polymerase II (the target of CDK9) were explored in selected cell lines including HuH7 and PLC5. The in vivo efficacy of dinaciclib on HCC was tested in mouse xenografts of HuH7 cells implanted subcutaneously. Knockdown of various CDKs using RNA interference was conducted to explore the mechanisms of dinaciclib. Results: Dinaciclib showed potent anti-proliferative activities in all the tested HCC cell lines. The IC50s to dinaciclib by the MTT assay did not significantly differ between cell lines with high Rb expression (8.5 to 20.1 nM) and cell lines with low Rb expression (9.4 to 15.6 nM). After 48 hours of dinaciclib treatment, HuH7 and PLC5 cells showed G2/M arrest in a dose-dependent manner. Apoptosis assays including sub-G1 fraction analysis, DNA fragmentation detection, and cleaved PARP-1 confirmed the occurrence of apoptosis in HuH7 and PLC5 cells treated with dinaciclib. Dinaciclib at the concentration near the IC50 inhibited the phosphorylation of Rb, RNA polymerase II, and ATM in HuH7 and PLC5 cells; it also inhibited the expressions of multiple anti-apoptotic proteins including Mcl-1, XIAP, and survivin. In xenograft studies with HuH7 cells, mice receiving dinaciclib had a significantly slower tumor growth rate compared with mice receiving vehicles. The TUNEL assay showed that tumors treated with dinaciclib exhibited higher apoptosis activity. Mice tolerated the dinaciclib treatment well without significant body weight change. Knockdown of CDK 1, 2, 5, and 9 using RNA interference showed that CDK1 and CDK9 may contribute the most to the efficacy of dinaciclib. Conclusions: Composite knockdown of CDK 1, 2, 5, and 9 with dinaciclib showed potent activity against HCC. (This study was supported by Ministry of Science and Technology, Taiwan [MOST-103-2314-B-002-181-MY2, MOST-103-2314-B-002-090, MOST-103-2314-B-002-092]). Citation Format: Yi-Hsin Liang, Yu-Yun Shao, Yong-Shi Li, Hang Lin, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu. Composite cyclin dependent kinase inhibition shows potent activity against hepatocellular carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2831.

Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation

Identification of Potent CDK9 Inhibitors with Novel Skeletons Via Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation

Abstract 2831: Composite Cyclin Dependent Kinase Inhibition Shows Potent Activity Against Hepatocellular Carcinoma

In silico discovery of potential PPI inhibitors for anti-lung cancer activity by targeting the CCND1-CDK4 complex via the P21 inhibition mechanism

Identification of Novel CDK 4/6 Inhibitors by High-throughput Virtual Screening

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer Through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.

Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy

Development of Promising CDK5 Inhibitors Using Structure‐Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Approach

The Inhibitors of CDK4/6 from a Library of Marine Compound Database: A Pharmacophore, ADMET, Molecular Docking and Molecular Dynamics Study

Computational identification of potential inhibitors targeting cdk1 in colorectal cancer

Synthesis and Structure-Activity Relationships of Cyclin-Dependent Kinase 11 Inhibitors Based on a Diaminothiazole Scaffold

3D-QSAR and Molecular Docking Approaches for the Identification of Novel Phyto-inhibitors of the Cyclin-dependent Kinase 4

Direct targeting of HSP90 with daurisoline destabilizes -catenin to suppress lung cancer tumorigenesis

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

Potent inhibitors targeting Cyclin-dependent kinase 9 discovered via virtual high-throughput screening and absolute binding free energy calculations

Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors

Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity

Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening